posted
The conference is today. I know of two Inv. banks that are there, and they are starting to realize this should be a $10 stock. I have 20k shares. Posts: 4381 | From: houston | Registered: Mar 2006
| IP: Logged |
posted
3 bids at .80. This will be way over $1 soon. I told you guys to back the truck up at .61. At $10 the market cap is 280 million. This is a 10-15 billion industry by 2010.
Posts: 4381 | From: houston | Registered: Mar 2006
| IP: Logged |
quote:Originally posted by HossTrader: This is the type of pink I love to find. I can find NOTHING that makes me question that this company is actually trying to do what they say they are doing. They are conducting real research into products for a real market. It isn't just a share printing op, or another company pretending to jump on a hot topic.
That being said, there are no guarantees this company will be successful, or they won't have to raise more capital.
But at least with this one, you are gambling on them developing the technology and bringing it to market instead of gambling on wether or not the ceo is full of ****.
Also, this is not a pink, its a BB.
Posts: 4381 | From: houston | Registered: Mar 2006
| IP: Logged |
Advanced Cell Technology To Present Progress Report on Product Development and ACTCellerate Platform at BIO Investor Forum
Business Wire "US Press Releases "
ALAMEDA, Calif.--(BUSINESS WIRE)--
Advanced Cell Technology, Inc.'s (OTCBB:ACTC) Michael West, Ph.D., Chairman, President and Chief Scientific Officer will be presenting at the 2006 BIO Investor Forum at the Palace Hotel, in San Francisco, California on October 19, 2006. The presentation is scheduled for 2:20 PM in the Sea Cliff room. Presentation slides and a live web cast may be accessed through the company's website at www.advancedcell.com.
Dr. West will discuss ACT's recently-published data on blastomere biopsy (a novel technique that allows human ES cell lines to be produced from a single embryonic cell), thereby demonstrating the feasibility of producing new human ES cell lines without disaggregating human embryos. In addition, Dr. West will discuss recently-published positive results in preclinical studies with the company's retinal pigment epithelial (RPE)cells, and an update on ACTCellerate. As previously announced by the company, ACTCellerate is a technology platform for isolating novel purified and scalable cell types from human embryonic stem cells. New results relating to novel propagating human heart progenitor and cranial neural crest cell lines isolated using the ACTCellerate technology will be presented.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
posted
Here it is. This is a $10-$20 stock masked as a .87. With under 30 million shares out., do the math. This is the best stock out there.
Dr. West will discuss ACT's recently-published data on blastomere biopsy (a novel technique that allows human ES cell lines to be produced from a single embryonic cell), thereby demonstrating the feasibility of producing new human ES cell lines without disaggregating human embryos.
Posts: 4381 | From: houston | Registered: Mar 2006
| IP: Logged |
WASHINGTON (Reuters) - Injecting human embryonic stem cells into the brains of Parkinson's disease patients may cause tumors to form, U.S. researchers reported on Sunday.
Steven Goldman and colleagues at the University of Rochester Medical Center in New York said human stem cells injected into rat brains turned into cells that looked like early tumors.
Writing in the journal Nature Medicine, the researchers said the transplants clearly helped the rats, but some of the cells started growing in a way that could eventually lead to a tumor.
Various types of cell transplants are being tried to treat Parkinson's disease, caused when dopamine-releasing cells die in the brain.
This key neurotransmitter, or message-carrying chemical, is involved in movement and Parkinson's patients suffer muscle dysfunction that can often lead to paralysis. Drugs can slow the process for a while but there is no cure.
The idea behind brain cell transplants is to replace the dead cells. Stem cells are considered particularly promising as they can be directed to form the precise desired tissue and do not trigger an immune response.
Goldman's team used human embryonic stem cells. Taken from days-old embryos, these cells can form any kind of cell in the body. This batch had been cultured in substances aimed at making them become brain cells.
Previous groups have tried to coax stem cells into becoming dopamine-releasing cells.
Goldman's team apparently succeeded and transplanted them into the rats with an equivalent of Parkinson's damage. The animals did get better.
But the grafted cells started to show areas that no longer consisted of dopamine-releasing neurons, but of dividing cells that had the potential to give rise to tumors.
The researchers killed the animals before they could know for sure, and said any experiments in humans would have to be done very cautiously.
Scientists have long feared that human embryonic stem cells could turn into tumors, because of their pliability.
Opponents of embryonic stem cell research cite such threats. Many opponents, including President George W. Bush and some members of Congress, believe it is immoral to destroy human embryos to obtain their stem cells.
Posts: 949 | From: Little Rock, AR | Registered: Dec 2005
| IP: Logged |
posted
ACTC has done it. Look at the money one state is trying to raise, and look at his key issue. Not damaging the embryo. ACTC has a patent on it. Love it.
In Wisconsin, stem cells are a central issue in a tight gubernatorial race. Democratic Gov. Jim Doyle is pushing to raise more than $750 million in public and private funding for stem-cell research facilities to augment those in Madison. Doyle's GOP challenger, U.S. Rep. Mark Green, has called for more than $25 million to study whether viable cells can be extracted without destroying embryos.
Posts: 4381 | From: houston | Registered: Mar 2006
| IP: Logged |
Dr. Lanza to be honored at 11th Annual Mass High Tech All-Star Awards Networking Celebration
WORCESTER, Mass., Oct 24, 2006 (BUSINESS WIRE) --
One of the world's leading authorities on embryonic stem cells, Robert Lanza, M.D., VP, Research and Scientific Development for Advanced Cell Technology, Inc. (OTCBB: ACTC) will be honored at the 11th Annual Mass High Tech All-Star Awards Networking Reception, October 25th from 6:00-8:30pm at the Westin Boston Waterfront Hotel.
Robert Lanza, M.D., has over 30 years of medical research experience, and has authored/edited 18 books, including "Essentials of Stem Cell Biology" and the "Handbook of Stem Cells" (as Editor-in-Chief). Last month, Dr. Lanza served as senior author for a paper that appeared in the journal Cloning and Stem Cells, in which ACTC scientists and their collaborators rescued visual function in animals using retinal pigment epithelial cells (RPE) derived from human embryonic stem (hES) cells. In August, Dr. Lanza served as senior author of a paper in Nature, describing a method for deriving stem cells using a single-cell approach that does not harm embryos.
He is a former Fulbright Scholar, and studied as a student in the laboratory of Jonas Salk (The Salk Institute), Richard Hynes (MIT), and Nobel laureates Gerald Edelman (Rockefeller University) and Rodney Porter (Oxford University). He also worked closely (and coauthored a series of papers) with the late Harvard psychologist B.F. Skinner and heart transplant pioneer Christiaan Barnard. Dr. Lanza received his undergraduate and medical degrees from the University of Pennsylvania, where he was both a University Scholar and Benjamin Franklin Scholar.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com..
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Copyright Business Wire 2006
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
Related Quotes Sym. Price Chg. ACTC Trade News 0.77 0 Advanced Cell Technology to Present Stem Cell Programs at Rodman & Renshaw`s Annual Healthcare Conference in New York
November 03, 2006 12:51:26 (ET)
ALAMEDA, Calif., Nov 03, 2006 (BUSINESS WIRE) -- Advanced Cell Technology (ACTC), Inc. (ACTC, Trade), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, today announced that Chief Executive Officer, William M. Caldwell, IV will be a featured presenter at Rodman & Renshaw's 8th Annual Healthcare Conference in New York City on November 6-8.
Mr. Caldwell will review ACTC's proprietary technologies and recent milestones in its mission to drive medically needed stem cell-based therapies to the clinic. He will discuss ACTC's stem cell-related technology platforms, and will spotlight the company's lead programs to develop novel stem cell therapies in the fields of vision, cardiovascular disease and dermal wound repair for scarless healing from burns, surgery and other causes.
ACTC's recent milestones include publication of the company's single cell blastomere technique for generating new embryonic stem cell lines without harming the embryo's potential for life and development. The Company also recently published positive progress in its retinal pigment epithelial (RPE) program, a therapeutic development initiative to develop stem cell-based treatment for certain diseases of the retina.
The Rodman & Renshaw conference will feature presentations from over 300 companies representing the medical device, pharmaceutical and biotechnology industries.
The conference will take place at the Palace Hotel at 455 Madison Ave., in New York, NY. The ACTC presentation is scheduled for 11:40 AM in the Kennedy II room, 4th floor.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com Copyright Business Wire 2006
Set Alerts
Create your Personalized SmartAlerts here.
Quotes
To get interactive quotes within this page, download Flash now
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Web Alert: Advanced Cell Technology Presents Stem Cell Technologies and Programs Today at Rodman & Renshaw Healthcare Conference in New York
November 06, 2006 06:30:09 (ET)
ALAMEDA, Calif., Nov 06, 2006 (BUSINESS WIRE) -- Advanced Cell Technology (ACTC), Inc. (ACTC, Trade), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, will present an overview of its stem cell-based therapeutic development programs and proprietary technologies today at the Rodman & Renshaw 8th Annual Healthcare Conference in New York City.
A live webcast of the presentation, by Chief Executive Officer William M. Caldwell, IV, will also be accessible online during the presentation and archived for 90 days. Details of the conference presentation and webcast are below.
WHAT: ACTC Presentation at Rodman & Renshaw 8th Annual Healthcare Conference WHO: Chief Executive Officer William M. Caldwell, IV WHEN: Today, November 6, 2006, at 11:40 a.m. EST. WHERE: Kennedy II Room, 4th Floor, Palace Hotel, 455 Madison Ave., New York, NY WEBCAST: An online webcast of the presentation will be accessible at www.advancedcell.com. ARCHIVE: A downloadable copy of the presentation will also be available on the Company's website at www.advancedcell.com/conference-presentations/. In the presentation, Mr. Caldwell will spotlight the company's technologies and programs to develop novel stem cell therapies in the fields of vision, cardiovascular disease and dermal wound repair for scarless healing from burns, surgery and other causes.
The Rodman & Renshaw conference will feature presentations from over 300 companies representing the medical device, pharmaceutical and biotechnology industries.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Mass.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group James Carbonara, Investors, 212-825-3210 Bill Douglass, Media, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com Copyright Business Wire 2006
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Advanced Cell Technology to Present at the 2006 PIPES Conference on November 7th
November 06, 2006 08:43:08 (ET)
ALAMEDA, Calif., Nov 06, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade) William M. Caldwell, IV, Chief Executive Officer and Michael D. West, Ph.D., President and Chief Scientific Officer, will present at the 2006 PIPES Conference at the Waldorf Astoria Hotel, on Tuesday, November 7th, 2006. Mr. Caldwell will present at 1:30pm. Dr. West will be giving a scientific update at 2:00 and 2:30pm.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications: Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com Copyright Business Wire 2006
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Looks to be getting a bit of a run this morning.
up 12%
-------------------- Life isn't about what you get out of it, it's about what you put into it. Posts: 24 | From: Fort Smith, AR | Registered: Oct 2006
| IP: Logged |
-------------------- Life isn't about what you get out of it, it's about what you put into it. Posts: 24 | From: Fort Smith, AR | Registered: Oct 2006
| IP: Logged |
posted
This is huge, the Dems. may take the Senate as well. I now have 30k. .
Posts: 4381 | From: houston | Registered: Mar 2006
| IP: Logged |
liberty01
unregistered
posted
i forgot about this page! ACTC no Brainer with Dems in. Ive been slowly adding since the .70's. Sorry for not posting in the .11 and up since then. Im ready for a fun ride, wait till everyone else gets the same idea!!!!! WHOOT WHOOOT!
IP: Logged |
posted
Meanwhile, Merck & Co. (MRK, Trade ) saw its shares fall 3.5% to $44.29. The drugmaker and Dow Jones Industrial Average component said late Tuesday that it's facing up to $5.58 billion in tax liabilities in the U.S. and Canada and that it plans to contest the matter with the two nations' tax authorities.
While most of the drug industry traded downward amid uncertainty what a change in control in at least one chamber on Capitol Hill will mean, stem-cell research companies rallied on the election results.
Several key members of the Republican leadership in Washington have been against lifting certain funding restrictions on organizations that conduct stem-cell research on human embryos. President Bush issued the only veto of his term in office earlier this year of a bill that would have encouraged embryonic stem-cell research.
"I hope and expect that these bills will re-emerge early in the next session," Advanced Cell Technology's chief executive officer, William Caldwell, told MarketWatch Thursday.
Advanced Cell Technology (ACTC, Trade ) shares were up 15% at 93 cents a share
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Advanced cell Tech up .12 on heels of pro Stem cell research Democrats house take over.
ACTC 0.93 0.12
Advanced Cell Technology Scientist Dr. Robert Lanza Invited to Address The National Academy of Sciences at Stem Cell Policy Meeting Advanced Cell Technology, Inc. (ACTC) (OTCBB:ACTC), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, announced today that Dr. Robert Lanza, Vice President of Research and Scientific Development of ACTC, will present before the National Academy of Sciences (NAS) at a special meeting to explore the latest developments in embryonic stem cell science and policy.
Dr. Lanza will make his presentation at the NAS's meeting of the Human Embryonic Stem Cell Research Advisory Committee, scheduled for November 7-8 in Washington, D.C. The meeting is dedicated to the furtherance of stem cell science and technology. His presentation will focus on ACTC's single-cell blastomere technique, which the company developed to derive new stem cell lines while preserving the embryo's potential for life and normal development.
The NAS, a prestigious society of distinguished scholars engaged in scientific research, has recruited Dr. Lanza to provide expert advice as they explore alternative ways to derive stem cells and make recommendations for the nation's public policy officials.
"We believe ACTC's technique for deriving stem cells without harming the embryo's potential for life can be an important consideration for the NAS as they form their recommendations to public officials," said William M. Caldwell IV, Chief Executive Officer of Advanced Cell Technology.
Advanced Cell Technology recently announced that company scientists demonstrated the ability to generate new human embryonic stem cell lines by adapting a proven technique already used at in vitro fertilization labs to determine genetic health. The ACTC approach maintains the embryo's potential for life, addressing one of the key debates in stem cell research.
ACTC's mission is to develop stem cell based treatments and therapies for a broad range of disease and injuries. Embryonic stem cells promise to provide a well-characterized and reproducible source of replacement tissue for human clinical studies. One of ACTC's lead development programs applies human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) for the treatment of retinal degenerative diseases such as macular degeneration and retinitis pigmentosa. Another development program focuses on the use of hESC-derived hemangioblasts for vascular restoration of organs and limbs.
Since 1863, the nation's political leaders have often turned to the NAS for advice on the scientific and technological issues that frequently pervade policy decisions. Most of the NAS's science policy and technical work is conducted by its operating arm, the National Research Council, created expressly for this purpose. These non-profit organizations provide a public service by working outside the framework of government to ensure independent advice on matters of science, technology, and medicine.
Dr. Lanza will be speaking at 10:30 a.m. on Nov. 7. A live audio webcast of the event, along with Dr. Lanza's PowerPoint presentation, will be available at www.advancedcell.com.
About Advanced Cell Technology, Inc.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information, please visit: www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
![[Wink]](wink.gif)
![[Eek!]](eek.gif)
![[Smile]](smile.gif)
